Abiraterone acetate is an inhibitor of 17α-hydroxylase/C17, 20-lyase (CYP17A1) that blocks the synthesis of androgens by the adrenal glands 6 and prostate cancer cells themselves, 7 thus depriving these cells of non-testicular sources of androgens. Abiraterone is approved for the treatment of mCRPC both in patients who have been previously treated with docetaxel chemotherapy, 8 and in patients who are chemotherapy naïve. 9 More recently, abiraterone has been reported to prolong overall survival in patients with treatment-naïve metastatic hormone sensitive prostate cancer (mHSPC) when combined with initial ADT. 10, 11 Thus, therapeutic strategies to enhance and prolong the anti-cancer activity of abiraterone are critical to optimize outcomes in patients with metastatic prostate cancer. A variety of mechanisms of resistance to abiraterone have been described in the literature, 12 including maintaining hormonal signaling through amplification, mutations, and/or splice variants of the AR, or overexpression of
; transdifferentiation to a non-AR dependent state 13 (including neuroendocrine prostate cancer); and activation of alternate survival signaling pathways.
Cabozantinib is a multi-kinase inhibitor with activity against MET and VEGFR2, 14 as well as multiple other kinases including RET, KIT,
FLT-1/3/4, TIE2, and AXL. 15 Single agent cabozantinib has demonstrated meaningful clinical activity in metastatic CRPC, with results of a Phase II study demonstrating improvements in bone scans, pain, and even measurable soft tissue disease in some patients. 16 In the randomized Phase III COMET-1 trial, 17 cabozantinib did not improve overall survival compared with prednisone, however, it did improve bone scan response and progression-free survival.
As such, cabozantinib has shown some activity in very late stage mCRPC but further development would require identification of predictive biomarkers or rational therapeutic combinations likely earlier in the disease process. One such potential therapeutic combination is cabozantinib with abiraterone. In pre-clinical models of CRPC, abiraterone treatment led to a compensatory increase in phosphorylation of the insulin-like growth factor I receptor (IGFIR) pathway with downstream activation of MEK1/2 and ERK1/2, 18 suggesting this pathway as an alternate signaling pathway conferring resistance to abiraterone. In vivo, cabozantinib inhibited abiraterone induction of IGFIR and downstream activation of p-MEK1/2 and p-ERK1/2 and enhanced the anti-tumor activity of abiraterone. 18 These studies would suggest that cabozantinib plus abiraterone could be an effective therapeutic strategy for mCRPC or metastatic hormone sensitive prostate cancer. Thus, we conducted a Phase I study to define the recommended phase 2 dose (RP2D) or MTD of cabozantinib when combined with abiraterone, as well as to assess the toxicity and preliminary anti-tumor activity of abiraterone in combination with cabozantinib in mCRPC.
| PATIENTS AND METHODS

| Study design and treatments
This two-stage study consisted of a dose-escalation stage (Part A)
followed by a dose-expansion stage (Part B). Part A employed a standard 3 + 3 design to evaluate three dose levels of cabozantinib (20, 40, and 60 mg/day orally) in combination with abiraterone acetate 1000 mg orally daily and prednisone 5 mg orally twice daily to establish the recommended phase two doses (RP2D) of the combination. Part B was an expansion phase including up to three dose levels determined to be safe and tolerable in Part A. The cohorts could be expanded to a maximum of 12 subjects at each dose level (including the subjects from Part A). Treatment in all cohorts was continued until disease progression, unacceptable toxicity, initiation of another cytotoxic or investigational agent, or discontinuation at the investigator's discretion.
| Study population
The study enrolled patients with mCRPC with symptomatic or radiographic progression from prior therapy. 
| Antitumor effect-serologic response
PSA responses are reported as the percentage change from the time of their first treatment with therapy. PSA levels were assessed before study entry then every 4 weeks thereafter. The maximum decline in PSA that occurred at any point after treatment is reported using a waterfall plot. PSA progression was the date that a 25% or greater increase and an absolute increase of 2 ng/mL or more from the nadir was documented, which was confirmed by a second value obtained three or more weeks later.
| Antitumor effect-radiographic response
As a secondary endpoint, measurable and/or non-measurable disease were assessed by RECIST 1.1 criteria using 99m Tc-MDP skeletal scintigraphy and contrast-enhanced diagnostic CT of the abdomen and pelvis. Imaging studies were obtained at baseline, and participants were initially reevaluated every 8 weeks (within 7 days prior to day 1 of the subsequent cycle). After the completion of 12 cycles of therapy, participants underwent radiographic evaluation every 12 weeks (within 7 days prior to day 1 of the subsequent cycle). Confirmatory scans were obtained at least 4 weeks following initial documentation of an objective response.
Radiographic progression as defined by RECIST 1.1 and Prostate
Cancer Clinical Trials Working Group 2 (PCWG2) criteria 26 and response assessments were prospectively performed by independent radiologist in the DF/HCC imaging core.
| Analysis methods
All disease outcomes or response assessments were performed on an intent-to-treat ( Per the original protocol, patients were discontinued from study for progressive disease due to radiographic progression by PCWG2 criteria, 26 or in the absence of radiographic progression if there was symptomatic progression or changes in the participant's condition rendering the participant unacceptable for further treatment in the opinion of the treating investigator. This latter group of patients were defined on retrospective analysis as having progressed due to "no longer clinically benefiting" (NLCB) as suggested by PCWG3 criteria, 28 which were published after this study was conducted. Time to event outcomes, such as: (i) time to PSA progression; (ii) time to radiographic progression by PCWG2 criteria 26 per original protocol; (iii) time to progression as defined as the earlier of radiographic progression (PCWG2) 26 or clinician assessment of NLCB 28 ; and (iv) overall survival (OS) were estimated using the Kaplan-Meier method. had previously received docetaxel chemotherapy, and 4/27 patients (14.8%) had visceral metastases (Table 1) . 
| Dose-limiting toxicities
| Adverse events
Of the 27 patients included in the safety population, 13 patients (48%) experienced maximum grade 3 AEs, and four patients (15%) experienced grade 4 AEs: two from the cabozantinib 40 mg cohort and two from the 60 mg cohort ( Table 2 ). All four grade 4 events (renal disorder and appendicitis at the 40 mg dose level; aortic valve disease and hyperglycemia at the 60 mg dose level) seen in this study were indicated by the treating investigator to be unrelated to abiraterone and cabozantinib. Twenty-six of 27 patients reported treatment related AEs (Table 3) ; 15 patients had maximum grade ≥3 treatment-related AEs of which 12 (80%) were felt related to cabozantinib: 3 patients at 20 mg dose, 7 at 40 mg dose and two at 60 mg dose.
The most common treatment-related grade ≥2 AEs (all cohorts)
were hypertension (22.2%), hypophosphatemia (18.5%), elevated AST (11.1%), palmar-plantar erythrodysesthesia (11.1%) and musculoskeletal and connective tissue disorders (11.1%: one herniated disc, two muscle weakness). Treatment-related Grade 3 AEs experienced by more than one patient (all cohorts) included infections (11.1%), hypophosphatemia (11.1%), thromboembolic events (n = 2), anemia (n = 2), elevated lipase (n = 2), and elevated ALT (n = 2) ( 
| Pharmacokinetics
The geometric mean C min ss for abiraterone 1000 mg QD was similar in patients receiving cabozantinib at doses of 20 mg QD (14.1 ± 4.5 ng/mL, n = 11) and 40 mg QD (15.2 ± 7.6 ng/mL, n = 8).
Data was available for only two patients treated with 60 mg cabozantinib precluding meaningful comparisons with data from the other two dose levels. The median C min ss for abiraterone for all 21 patients was 16.0 ng/mL (range, 5.9-29.8 ng/mL). The geometric mean C min ss for cabozantinib given once daily was 213 ± 109 ng/mL for the 20 mg QD dose (n = 11) and 434 ± 146 ng/mL for patients treated with 40 mg QD (n = 8). The geometric mean dose-normalized C min ss of cabozantinib for all 21 patients was 11.1 ± 4.9 ng/mL/mg.
| Description of efficacy results
As of data lock October 24, 2017, twenty-six (26) patients had been discontinued from study treatment, while one patient remained on Cabozantinib is an intriguing partner for combination treatment with abiraterone given its mechanism of action. As a multi-kinase inhibitor, it can simultaneously target critical signaling pathways as well as compensatory pathways. For example, inhibition of compensatory upregulation of MET signaling with blockade of the VEGF pathway has been implicated as its major mechanism of action in renal cell carcinoma. 38, 39 Two of the major targets of cabozantinib, MET, and VEGFR2, have both been mechanistically implicated in the development of castration resistance in patients. 40 Interestingly, in a PTEN/p53-deficient genetically engineered mouse model, the antitumor activity of cabozantinib was demonstrated not to be related to inhibition of MET but rather to activation of a neutrophil-mediated anticancer innate immune response. 41 In a preclinical model of prostate cancer, it has been demonstrated that cabozantinib can inhibit compensatory upregulation of the IGF1R/MEK/ERK pathway in prostate cancer cells induced by abiraterone treatment. 18 Clearly, further investigation is needed to clarify the mechanism by which cabozantinib may enhance the activity of abiraterone in patients.
Cabozantinib demonstrated interesting single-agent clinical activity in a phase 2 nonrandomized expansion study in castration-resistant prostate cancer (CRPC), demonstrating bone scan response rates of 73 and 45% in 100 mg (N = 93) and 40 mg (N = 51) cohorts, respectively.
16
In addition, there were improvements seen in measurable soft tissue disease, circulating tumor cells and bone biomarkers, along with improvements in pain, and analgesic use. 42 In these studies, the 100 mg dose of cabozantinib was associated with significant toxicity so a 60 mg dose was chosen for the subsequent phase 3 COMET-1 study, where patients were randomized to cabozantinib versus prednisone with primary endpoint of overall survival. The COMET-1 study demonstrated improvements in bone scan response, radiographic progression-free survival, symptomatic skeletal events, CTC conversions, and bone biomarkers but not PSA outcomes or overall survival.
Because the COMET-1 study did not demonstrate an OS benefit, the with minimal involvement of other CYP isozymes. 24, 46 In vitro studies using human hepatic microsomes showed that abiraterone is a moderate inhibitor of CYP3A4/5 and that cabozantinib inhibits the isozyme weakly.
Cabozantinib is not a potent inducer of CYP3A4/5 and the induction potential of abiraterone on CYP isozymes has not been reported. The pharmacokinetics of cabozantinib are readily altered by agents that significantly inhibit or induce CYP3A4 activity. 21 Systemic exposure to abiraterone was decreased by 55% when given to subjects that had been pretreated with the strong CYP3A4 inducer rifampin but not significantly affected when coadministered with the strong CYP3A4 inhibitor ketoconazole. 47 The plasma pharmacokinetics of erlotinib, an approved anticancer drug for which CYP3A4 metabolism represents a prominent route of its elimination, was not affected by the coadministration of cabozantinib in a phase I study in patients with solid tumors. 24 The current understanding of the pharmacokinetics and metabolism of abiraterone and cabozantinib therefore suggests that there is a relatively low potential for a clinically relevant alteration in the plasma pharmacokinetics of either drug when given concurrently. reported study. 50 The range of abiraterone concentrations seen in combination with cabozantinib in our study overlaps with ranges of C min ss in previous reports. The median abiraterone concentration seen in our study is numerically different from prior studies, though it is entirely possible that other unknown factors, such as differences in patient characteristics or their diets, the time that samples were collected relative to the prior dose, consistency in the daily dosing time, the analytical methods used to measure the drug concentration, or interpatient variability in the pharmacokinetics of the drug, contributed to the differences seen here. A more formal drug-drug interaction study would be needed to definitively determine if cabozantinib affects abiraterone levels. If cabozantinib were shown to mitigate the likelihood of low systemic abiraterone exposure in some patients, this could also increase the chance of clinical benefit as low abiraterone levels have previously been correlated with inferior outcomes. 50, 51 However, there is no evidence that this is the mechanism mediating potentially greater clinical benefit seen at the 40 mg dose level in this study compared to the 20 mg dose level as the abiraterone concentrations were nearly equivalent in these groups:
14.1 ± 4.5 ng/mL (n = 11) at the 20 mg dose and 15.2 ± 7.6 ng/mL (n = 8) at the 40 mg dose.
In conclusion, we have demonstrated safety, tolerability, and preliminary evidence of clinical activity with the combination of abiraterone and cabozantinib. The results of this trial provide important information to guide the design of a definitive comparative trial, which will more fully assess the ability of cabozantinib to increase duration of cancer control and overall survival in combination with abiraterone in patients with prostate cancer.
